Allogene Therapeutics Inc (NASDAQ:ALLO) has coverage initiated with a Outperform rating

Analyst Ratings For Allogene Therapeutics Inc (NASDAQ:ALLO)

Story continues below

Today, Cowen initiated coverage on Allogene Therapeutics Inc (NASDAQ:ALLO) with a Outperform.

There are 3 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Allogene Therapeutics Inc (NASDAQ:ALLO) is Buy with a consensus target price of $33.6667 per share, a potential 21.45% upside.

Some recent analyst ratings include

  • 11/5/2018-Allogene Therapeutics Inc (NASDAQ:ALLO) has coverage initiated with a Outperform rating
  • 11/5/2018-Allogene Therapeutics Inc (NASDAQ:ALLO) has coverage initiated with a Neutral ➝ Neutral rating and $29.00 price target
  • 11/5/2018-Allogene Therapeutics Inc (NASDAQ:ALLO) has coverage initiated with a Buy ➝ Buy rating and $31.00 price target
  • 11/5/2018-Allogene Therapeutics Inc (NASDAQ:ALLO) has coverage initiated with a Buy ➝ Buy rating and $41.00 price target


    Recent Trading Activity for Allogene Therapeutics Inc (NASDAQ:ALLO)
    Shares of Allogene Therapeutics Inc closed the previous trading session at 27,81 +0,12 0,43 % with shares trading hands.

    An ad to help with our costs